Bisphosphonates: AHFS 92:24

Claire Stark Toller; Sarah Charlesworth; Mary Mihalyo; Paul Howard; Andrew Wilcock

doi:10.1016/j.jpainsymman.2019.01.017

Bisphosphonates: AHFS 92:24

J Pain Symptom Manage. 2019 May;57(5):1018-1030. doi: 10.1016/j.jpainsymman.2019.01.017. Epub 2019 Feb 7.

Authors

Claire Stark Toller¹, Sarah Charlesworth¹, Mary Mihalyo¹, Paul Howard¹, Andrew Wilcock²

Affiliations

¹ Countess Mountbatten House (C.S.T.), University Hospital Southampton; Pharmaceutical Press (S.C.), London, United Kingdom; Mylan School of Pharmacy (M.M.), Duquesne University, Pittsburgh, Pennsylvania, USA; Mountbatten Hospice (P.H.), Isle of Wight, United Kingdom; and University of Nottingham (A.W.), Nottingham, United Kingdom.
² Countess Mountbatten House (C.S.T.), University Hospital Southampton; Pharmaceutical Press (S.C.), London, United Kingdom; Mylan School of Pharmacy (M.M.), Duquesne University, Pittsburgh, Pennsylvania, USA; Mountbatten Hospice (P.H.), Isle of Wight, United Kingdom; and University of Nottingham (A.W.), Nottingham, United Kingdom. Electronic address: andrew.wilcock@nottingham.ac.uk.

PMID: 30738144
DOI: 10.1016/j.jpainsymman.2019.01.017

Abstract

Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available via www.medicinescomplete.com. The series editors welcome feedback on the articles (hq@palliativedrugs.com).

Publication types

Review

MeSH terms

Animals
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
Diphosphonates / adverse effects
Diphosphonates / pharmacology
Diphosphonates / therapeutic use*
Hospice Care
Humans
Palliative Care

Substances

Bone Density Conservation Agents
Diphosphonates